Yahoo Malaysia Web Search

Sign In

Search results

  1. za.investing.com › news › company-newsLexicon Pharmaceuticals maintains stock target, Overweight rating

    1 day ago · 2024-05-31 15:09. On Friday, Piper Sandler reaffirmed its positive stance on Lexicon Pharmaceuticals (NASDAQ: LXRX ), maintaining an Overweight rating and a price target of $10.00 on the company's stock. The firm's outlook is buoyed by the anticipation of a significant year ahead for Lexicon, marked by several potential catalysts.

  2. themalaysianreserve.com › 2024/06/01 › rybrevant-amivantamabRYBREVANT® (amivantamab-vmjw) plus lazertinib is the only...

    2 hours ago · “These new data demonstrate the efficacy of RYBREVANT plus lazertinib, showing a significant reduction in the risk of disease progression or death compared to osimertinib in several high-risk subgroups of patients with EGFR-mutated NSCLC,” said Byoung Chul Cho, M.D., Ph.D., medical oncologist and professor in the Division of Medical Oncology at Yonsei Cancer Center, Yonsei University ...

  3. themalaysianreserve.com › 2024/06/01 › first-results-from-lateFirst results from late-breaking Phase 3 PALOMA-3 study show...

    2 hours ago · “The PALOMA-3 data show that subcutaneous amivantamab offers shorter infusion times and lower rates of infusion-related reactions and venous thromboembolism with pharmacokinetics and efficacy comparable to the current IV administration,” said Dr. Natasha B. Leighl *, medical oncologist at the Princess Margaret Cancer Centre in Toronto, Canada, and the presenting author.

  4. sg.finance.yahoo.com › news › first-results-breaking-phase-3First results from late-breaking Phase 3 PALOMA-3 study show...

    1 day ago · Johnson & Johnson announced today first data from the Phase 3 PALOMA-3 study evaluating subcutaneous (SC) amivantamab combined with lazertinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion (ex19del) or L858R mutations. Study results showed non-inferior efficacy and pharmacokinetics for SC ...

  5. za.investing.com › news › company-newsInvivyd appoints new Chief Commercial Officer ahead of PEMGARDA...

    1 day ago · Investing.com. 2024-05-31 17:02. WALTHAM, Mass. - Invivyd, Inc. ( NASDAQ :IVVD), a company focused on developing treatments for viral infectious diseases, announced the appointment of Timothy Lee as its new Chief Commercial Officer. Lee's extensive experience in the pharmaceutical industry is expected to enhance the company's commercial ...

  6. business.malvern-online.com › malvern-online › articlePfizer’s LORBRENA® CROWN Study Shows Majority of Patients with...

    1 day ago · Pfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression

  7. business.decaturdailydemocrat.com › decaturdailydemocratPfizer’s LORBRENA® CROWN Study Shows Majority of Patients with...

    1 day ago · Pfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression